NewsMarkets

Health

Cholesterol Drug Trial Fails to Show Benefit for Lipoprotein(a) Reduction

Scientists are reassessing the future of lipoprotein(a) therapies after a major clinical trial failed to demonstrate a significant benefit.

1 publisher · 1 article · first seen 3 Nov 2026 · updated 4d ago

Headline and summary written by an AI model from the linked article; not reviewed by a person. How this was made

This story has stopped developing; this page is its permanent record. More from that day

The story so far

1 publisher has covered this in 1 article since 3 Nov 2026. Nature published first, on 3 November at 00:00 UTC.

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. This cholesterol drug promised to be a game-changer. Why did it flop in the clinic — and is there still hope? Nature ·
Embed this story

Paste this into any web page to show the live odds, with a link back here.